Related Experiment Video
Updated: May 12, 2025
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Successful Treatment of Severe Nail Lichen Planus with Janus Kinase 1 Inhibitor Abrocitinib
Yingzhi Luo1, Jian Wu2, Xingyun Zhao1
1Department of Dermatology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People's Republic of China.
Abstract:
Nail lichen planus (NLP) is a chronic inflammatory disease that presents a significant therapeutic challenge. It can progress rapidly, leading to impaired nail morphology and function. Currently, there is no established standard therapy due to limited efficacy or potential for significant adverse reactions. In this report, we present a case of very severe NLP successfully treated with the Janus kinase 1 (JAK1) inhibitor abrocitinib, with no associated discomfort.
Insights
Nail lichen planus (NLP) is a difficult-to-treat inflammatory condition. A severe case of NLP was effectively managed using abrocitinib, a Janus kinase 1 (JAK1) inhibitor, with no adverse effects.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Nail lichen planus (NLP) is a chronic inflammatory condition impacting nail morphology and function.
- Current therapeutic options for NLP are limited by efficacy and adverse reactions.
- There is a need for novel, effective treatments for severe NLP.
Observation:
- A patient presented with very severe nail lichen planus.
- The patient's condition was refractory to existing treatments.
- The patient was treated with abrocitinib, a Janus kinase 1 (JAK1) inhibitor.
Findings:
- Abrocitinib demonstrated significant efficacy in treating severe NLP.
- The treatment resulted in successful management of the condition.
- No adverse effects or discomfort were reported during abrocitinib therapy.
Implications:
- Abrocitinib represents a potential new therapeutic strategy for severe NLP.
- Targeting Janus kinase 1 (JAK1) may be beneficial in managing inflammatory nail diseases.
- Further research is warranted to explore abrocitinib's role in treating nail lichen planus.
